Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Quest Diagnostics delivered a mixed yet overall positive performance in its recent financial results.</li><li>The company reported a 2.5% increase in total revenues, with base business revenues growing by nearly 4%.</li><li>This growth is attributed to the expansion of new physician and hospital customers and an improved test mix, with advanced diagnostics seeing greater adoption and healthcare utilization remaining strong.</li></ul>

Quest Diagnostics delivered a mixed yet overall positive performance in its recent financial results.The company reported a 2.5% increase in total revenues, with base business revenues growing by nearly 4%.This growth is attributed to the expansion of new physician and hospital customers and an improved test mix, with advanced diagnostics seeing greater adoption and healthcare utilization remaining strong.

Quest Diagnostics: Will The Acquisition of Canadian Lab Provider LifeLabs Be A Game Changer? - Major Drivers

<ul><li>Quest Diagnostics' earnings promising headlines such as the company delivering nearly 6% base business revenue growth in Q1, Quest's ability to sustain strong commercial focus on physicians and hospitals, continued investment in automation and artificial intelligence (AI), and a reevaluation of the guidance for the full year.</li><li>Quest Diagnostics' Q1 growth was driven by its significant focus on physicians and hospitals.</li><li>The company's broad health plan access allowed it to leverage sustained high rates of health care utilization to drive new customer growth.</li></ul>

Quest Diagnostics' earnings promising headlines such as the company delivering nearly 6% base business revenue growth in Q1, Quest's ability to sustain strong commercial focus on physicians and hospitals, continued investment in automation and artificial intelligence (AI), and a reevaluation of the guidance for the full year.Quest Diagnostics' Q1 growth was driven by its significant focus on physicians and hospitals.The company's broad health plan access allowed it to leverage sustained high rates of health care utilization to drive new customer growth.

Quest Diagnostics: Strengthening Revenue Growth Across Core Services! - Major Drivers

<ul><li>Quest Diagnostics Incorporated's fourth quarter and full year 2023 earnings call highlighted the company's strategy to focus on top-line growth across core customer channels and increase profitability.</li><li>In 2023, the company delivered 7% revenue growth in its base business and achieved its earnings commitments as it shifted away from COVID-19 testing.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Quest Diagnostics Incorporated's fourth quarter and full year 2023 earnings call highlighted the company's strategy to focus on top-line growth across core customer channels and increase profitability.In 2023, the company delivered 7% revenue growth in its base business and achieved its earnings commitments as it shifted away from COVID-19 testing.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Quest Diagnostics:  Continued Investment in New Technologies and Automated Solutions! - Major Drivers

<ul><li>Quest Diagnostics delivered a solid result and managed an all-around beat in the quarter.</li><li>Quest Diagnostics remained focused on driving growth through specialized advanced diagnostics, acquisitions, and operational improvements.</li><li>We give Quest Diagnostics Incorporated a 'Hold' rating with a revised target price.</li></ul>

Quest Diagnostics delivered a solid result and managed an all-around beat in the quarter.Quest Diagnostics remained focused on driving growth through specialized advanced diagnostics, acquisitions, and operational improvements.We give Quest Diagnostics Incorporated a 'Hold' rating with a revised target price.

Quest Diagnostics: Can The Haystack Acquisition & The Enhancements To The Cancer Diagnostics Portfolio Give Them A Boost? - Key Drivers

<ul><li>Quest managed to surpass the revenue as well as the earnings expectations of Wall Street.</li><li>The company experienced strong growth in its base business, particularly in physician and health system lab services.</li><li>The quarter saw positive developments, including increased volume growth in their base business and successful wins in reference and professional lab services.</li></ul>

Quest managed to surpass the revenue as well as the earnings expectations of Wall Street.The company experienced strong growth in its base business, particularly in physician and health system lab services.The quarter saw positive developments, including increased volume growth in their base business and successful wins in reference and professional lab services.

Quest Diagnostics Incorporated: New Liquid Biopsy Technology & Other Drivers

United States

Quest Diagnostics Incorporated provides diagnostic testing, information, and services.  The Company operates a national network of full-service laboratories, rapid response laboratories, and patient service centers.  Quest Diagnostics provides esoteric testing, routine medical testing, drugs of abuse testing, and non-hospital-based anatomicpathology testing.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Quest Diagnostics (DGX US)

Quest Diagnostics: Will The Acquisition of Canadian Lab Provider LifeLabs Be A Game Changer? - Major Drivers

Quest Diagnostics delivered a mixed yet overall positive performance in its recent financial results. The company reported a 2.5% increase in...

Baptista Research

Quest Diagnostics: Strengthening Revenue Growth Across Core Services! - Major Drivers

Quest Diagnostics' earnings promising headlines such as the company delivering nearly 6% base business revenue growth in Q1, Quest's ability to...

Baptista Research

Quest Diagnostics: Continued Investment in New Technologies and Automated Solutions! - Major Drivers

Quest Diagnostics Incorporated's fourth quarter and full year 2023 earnings call highlighted the company's strategy to focus on top-line growth...

Baptista Research

Quest Diagnostics: Can The Haystack Acquisition & The Enhancements To The Cancer Diagnostics Portfolio Give Them A Boost? - Key Drivers

Quest Diagnostics delivered a solid result and managed an all-around beat in the quarter. Quest Diagnostics remained focused on driving growth...

Baptista Research

Quest Diagnostics Incorporated: New Liquid Biopsy Technology & Other Drivers

Quest managed to surpass the revenue as well as the earnings expectations of Wall Street. The company experienced strong growth in its base...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)